% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

  • billyteex1 billyteex1 Nov 15, 2006 1:19 PM Flag

    First quarter 2007

    From the revenue numbers 31.2M to 41.2m we could sees EPS of .43 to .61 for the first quarter. Watch for analyst updates on projects for next year.

    EPS was figutred using 8M in expenses divide by 54M shares.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Analyst are loading up their customer base on shares of SUPG. Next year financial picture could easily be:

      12.2M Nipent deferment
      14.0M Nipent acceleration
      15.0M Dacogen royalities could be 20.M+
      10.0M Nipent EU deal...estimated total deal at 25M
      15.0M Dacogen Milestone EU approval MDS...could be 23.75M
      6.0M Interest on 74M in cash
      72.2M Total

      32.0M Expenses
      40.0M Profit or .71 EPS for the year!!!!!!!!!!

      Do the math!!!!!! SUPG could have 110M in cash on 12/31/07

      • 2 Replies to billyteex1
      • Billy, you estimated last quarter with fabulous numbers. What happened to last quarter and why has supg dropped from $5.78 to $5.04 ? I have many shares of supg however those bashers do point out how you keep on pumpimg supg regardless of actually numbers. Can you tell us the truth instead of pumping up supg.

      • BINGO....and if SUPG partners up on their pipeline you could see expenses (cash burn) decrease and cash position greatly increase. Watch for Orethecin/pipeline spin out. I believe combining one of SUPG pipeline and Orethecin will be announced soon. This stock could be flirting with $20 late next year....unless MGI wakes up and smells the coffee.